Can I Take Reishi Mushroom with Evenity (Romosozumab)?

What Is Romosozumab (Evenity) and How Does It Work?

Romosozumab is a humanized monoclonal antibody that binds and inhibits sclerostin, a glycoprotein produced by osteocytes that normally suppresses bone formation. Blocking sclerostin produces a dual effect: increased bone formation and decreased bone resorption simultaneously, a combination unique among approved osteoporosis therapies. The FDA approved romosozumab in April 2019 for postmenopausal women with severe osteoporosis at high fracture risk, and it is given as two 105 mg subcutaneous injections (total 210 mg) once monthly for exactly 12 months.

Clinical Efficacy at a Glance

The FRAME trial (N=7,180) showed that 12 months of romosozumab reduced new vertebral fractures by 73% compared with placebo (P<0.001) [1]. The ARCH trial (N=4,093) then compared romosozumab followed by alendronate against alendronate alone and found a 48% reduction in new vertebral fractures and a 27% reduction in hip fractures in the sequential romosozumab arm [2].

The Cardiovascular Black Box Warning

Evenity carries an FDA black box warning for increased risk of myocardial infarction, stroke, and cardiovascular death. In ARCH, serious cardiovascular events occurred in 2.5% of the romosozumab group vs. 1.9% of the alendronate group [2]. This warning is directly relevant to the reishi discussion below, because reishi has its own cardiovascular and coagulation effects.

What Is Reishi Mushroom and Why Do People Take It?

Reishi (Ganoderma lucidum) is a wood-decay fungus used in East Asian traditional medicine for centuries. Modern consumers take it primarily for immune support, stress reduction, and general longevity. Active constituents include beta-glucan polysaccharides (notably lentinan-like beta-1,3/1,6-glucans) and lanostane-type triterpenes (ganoderic acids A through Z and beyond).

What the Research Actually Shows

A 2016 Cochrane review assessed reishi for cancer patients and found insufficient evidence to recommend or discourage its use as a primary treatment, though it noted possible benefits as adjunct therapy and flagged anticoagulant effects as a safety concern [3]. A 2021 systematic review in the Journal of Ethnopharmacology (examining 49 human studies) found that reishi preparations modestly reduced fasting blood glucose and triglycerides in some populations but produced heterogeneous results across preparations and doses [4].

Bioactive Compounds That Matter for Drug Interactions

The triterpenes are the most pharmacologically active fraction from an interaction standpoint. Ganoderic acids inhibit thromboxane B2 synthesis and reduce ADP-induced platelet aggregation in vitro [5]. Separately, the polysaccharide fraction stimulates macrophage activation, natural killer cell activity, and dendritic cell maturation, as documented in a 2019 review in Frontiers in Immunology [6].

These two actions, antiplatelet and immune-activating, are where clinically meaningful interactions with romosozumab could arise.

Is There a Direct Pharmacokinetic Interaction?

Pharmacokinetic interactions occur when one agent alters the absorption, distribution, metabolism, or excretion of another. For romosozumab specifically, this risk is low.

Why Romosozumab Bypasses CYP450

Romosozumab is a large monoclonal antibody (molecular weight approximately 136 kDa). Large biologics are not metabolized by cytochrome P450 enzymes in the liver. They are instead catabolized by the same proteolytic pathways that degrade endogenous immunoglobulins. Because reishi's pharmacologically active triterpenes and polysaccharides do not meaningfully inhibit or induce CYP3A4, CYP2C9, or CYP2D6 at doses used in typical supplements, the plasma concentration of romosozumab is unlikely to be altered by reishi co-administration [7].

Bioavailability Considerations

Romosozumab is administered subcutaneously, bypassing the gut entirely. Reishi compounds that might theoretically affect intestinal transporters (P-glycoprotein, OATP) are therefore irrelevant to romosozumab's absorption.

Bottom line on pharmacokinetics: The pharmacokinetic interaction risk between reishi and romosozumab is low at typical supplement doses.

The Pharmacodynamic Concerns: Where Real Risk Lives

Pharmacodynamic interactions occur when two agents produce overlapping or opposing biological effects, regardless of how each is metabolized. This is where the reishi-romosozumab conversation gets more nuanced.

Concern 1: Anticoagulant and Antiplatelet Potentiation

Romosozumab's black box warning already places it in patients who are often older postmenopausal women, a population that may be on aspirin, clopidogrel, or anticoagulants such as apixaban or warfarin for cardiovascular risk. Adding reishi compounds with known antiplatelet activity stacks bleeding risk.

A 2004 study in Phytotherapy Research demonstrated that reishi extract (1.5 g/day equivalent) significantly inhibited ADP-induced platelet aggregation in healthy volunteers [8]. A case series published in the American Journal of Hematology documented two patients taking reishi who experienced prolonged bleeding times, one of whom was also on low-dose aspirin [9].

Romosozumab itself is not an anticoagulant. However, in patients who are already on antiplatelet or anticoagulation therapy, adding reishi to that stack is the actual clinical risk. The drug-supplement interaction here is indirect but real.

Concern 2: Immune Modulation and the RANKL-OPG Axis

This is the concern with the least clinical data but the most plausible biological mechanism.

Romosozumab works partly by suppressing osteoclast activity through downstream effects on the RANKL (receptor activator of nuclear factor kappa-B ligand) and OPG (osteoprotegerin) system. Reishi polysaccharides have been shown in preclinical studies to activate macrophages and T-lymphocytes [6]. Activated macrophages can upregulate RANKL expression. In theory, strong immune activation from reishi could partially counteract the anti-resorptive arm of romosozumab's dual mechanism.

This mechanism is speculative because no published human trial has measured bone turnover markers in patients taking both romosozumab and reishi simultaneously. The concern is biologically plausible but not clinically proven.

The HealthRX Three-Level Interaction Framework classifies this combination as follows:

| Level | Criterion | Reishi + Romosozumab | |-------|-----------|----------------------| | 1. PK risk | CYP450 / transporter overlap | Low | | 2. PD risk direct | Same receptor or pathway | Low | | 2. PD risk indirect | Convergent biology affecting outcome | Moderate (RANKL axis, immune activation) | | 3. Complication amplification | Worsens known drug adverse effect | Moderate (bleeding, CV risk stack) |

Overall classification: Moderate theoretical risk. Disclose and monitor, do not self-discontinue Evenity.

Concern 3: Cardiovascular Signal Amplification

Because romosozumab already carries a cardiovascular black box warning, any supplement with vasoactive properties warrants additional caution. Reishi's ganoderic acids have antihypertensive effects in some studies, including a small trial showing a 6 mmHg reduction in systolic blood pressure after 12 weeks of 240 mg/day extract [10]. Additive blood pressure lowering is generally benign or even beneficial, but it can become relevant in patients on antihypertensives who are also receiving romosozumab.

What the Guidelines Say About Supplements and Osteoporosis Biologics

The American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis state: "Patients on pharmacologic therapy for osteoporosis should be counseled that herbal and dietary supplements are not reviewed by the FDA for efficacy or safety and that potential interactions with prescribed agents should be discussed with their clinician before initiation." [11]

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in men similarly cautions that "concurrent use of non-prescription supplements has not been evaluated in clinical trials of bone-active medications." [12]

Neither guideline specifically names reishi mushroom, which reflects the absence of head-to-head trial data rather than a judgment that reishi is safe.

Monitoring Parameters If You Are Already Taking Both

If you are already taking reishi mushroom and your provider starts romosozumab, or if you started reishi after your first Evenity injection, the following monitoring approach is reasonable while you discuss the combination with your clinician.

Bone Turnover Markers

Romosozumab produces a rapid rise in the bone formation marker procollagen type 1 N-terminal propeptide (P1NP), typically peaking at 1 to 3 months, and a decline in the bone resorption marker C-terminal telopeptide (CTX). The Endocrine Society recommends checking P1NP and CTX at 3 to 6 months to confirm a therapeutic response [12]. If your bone turnover markers do not move as expected, supplement interference is one differential to raise.

Bleeding and Bruising Assessment

Your prescriber should ask at each monthly injection visit whether you have noticed unusual bruising, prolonged bleeding from cuts, or spontaneous gingival bleeding. These are not expected side effects of romosozumab alone. Their appearance in a patient also taking reishi should prompt a formal bleeding time or platelet function assessment.

Liver Function

High-dose reishi (above 2 g/day of extract) has been associated with rare cases of hepatotoxicity. A 2004 case report in the Journal of Hepatology described fulminant hepatic failure in a patient taking powdered reishi at 3 g/day for 8 months [13]. Romosozumab does not cause hepatotoxicity at approved doses, but baseline and periodic liver function tests (ALT, AST) are reasonable if the patient takes high-dose reishi.

Practical Recommendations: What to Do

If You Have Not Yet Started Reishi

Tell your Evenity prescriber before starting reishi. The conversation takes under two minutes and gives your clinician the context needed to document the supplement in your chart and decide whether additional monitoring is warranted. This is the simplest possible risk-mitigation step.

If You Are Already Taking Both

Do not stop romosozumab on your own. Evenity is a 12-month course with a defined therapeutic window. Stopping early reduces efficacy. Bring your reishi supplement (brand, dose, frequency) to your next appointment. Your prescriber may decide the dose and formulation of reishi you take carries negligible risk, or they may recommend stopping the supplement for the 12-month course duration.

Timing and Dose Separation

Unlike small-molecule drugs where dose separation meaningfully reduces pharmacokinetic overlap, there is no established dose-separation window that eliminates the pharmacodynamic concerns described above. Reishi's immune-modulating and antiplatelet effects are not acutely dependent on peak plasma concentrations; they accumulate over days to weeks of regular use. Timing reishi away from injection day does not resolve the interaction concern.

Reishi Formulation Matters

The antiplatelet evidence is strongest for standardized ethanolic extracts (often labeled as containing 10 to 30% polysaccharides and 2 to 6% triterpenoids). Reishi teas and lightly processed powders at culinary doses (under 500 mg dry weight equivalent per day) carry lower bioactive concentrations and likely lower interaction potential. This is worth discussing with your clinician if you are committed to continuing reishi for a specific reason.

Special Populations

Patients with Cardiovascular Disease

The FDA label for romosozumab states it should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Patients with cardiovascular disease who are nonetheless on Evenity carry the highest risk profile for the reishi combination, given the converging cardiovascular signals. This group should avoid reishi supplementation during the romosozumab treatment period.

Patients on Anticoagulants

Patients taking warfarin, apixaban, rivaroxaban, or clopidogrel alongside romosozumab face a three-way interaction risk: the anticoagulant's direct effect, romosozumab's cardiovascular black box context, and reishi's antiplatelet activity. Natural Medicines Database classifies the reishi-warfarin interaction as "moderate," with a recommendation to monitor INR more frequently [7]. Adding romosozumab into this combination warrants a frank conversation with both the prescribing endocrinologist and the cardiologist or hematologist managing anticoagulation.

Patients with Autoimmune Conditions

Reishi's immune-activating properties could theoretically worsen autoimmune conditions. Patients with rheumatoid arthritis-associated osteoporosis who are on romosozumab and any biologic immunosuppressant should discuss reishi with their rheumatologist, not just their bone-health provider.

The Evidence Gap: What We Do Not Know

No published randomized controlled trial or prospective cohort study has examined reishi and romosozumab together in human subjects. The interaction concerns described in this article are grounded in:

1. The established pharmacology of each agent independently.
2. Mechanistic studies of reishi constituents (mostly in vitro or animal data).
3. Extrapolation from reishi interactions with other anticoagulant or antiplatelet agents.
4. The clinical pharmacology of romosozumab's dual mechanism.

This is a meaningful evidence gap. It means the risk cannot be precisely quantified. It does not mean the combination is safe. The default clinical posture with any pharmacologically active supplement added to a biologic medication for a serious condition like severe osteoporosis is to disclose, document, and monitor.

Key Takeaways

Romosozumab (Evenity) and reishi mushroom do not share a CYP450 metabolic pathway, so a pharmacokinetic crash is not the primary worry. The concerns that are real are pharmacodynamic: reishi's antiplatelet triterpenes add bleeding risk on top of romosozumab's cardiovascular warning, and reishi's immune-activating polysaccharides could theoretically interfere with the RANKL-OPG biology that gives romosozumab its anti-resorptive effect.

The AACE guidelines explicitly call for clinician disclosure of all supplements before or during pharmacologic osteoporosis therapy [11]. That guidance applies directly here.

If you are 12 months into a romosozumab course, every monthly injection is working toward a fracture risk reduction that FRAME documented as 73% for vertebral fractures [1]. No reishi supplement has data showing it reduces fracture risk by any measurable amount. The risk-benefit calculation for this combination favors transparency with your prescriber and, in most cases, pausing reishi for the duration of the 12-month Evenity course.